Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

[1]  T. Olivier,et al.  Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm , 2021, Translational oncology.

[2]  S. Loi,et al.  ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  L. Carey,et al.  Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). , 2021 .

[4]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[5]  T. Powles,et al.  Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. , 2021, The New England journal of medicine.

[6]  T. Haddad,et al.  Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. , 2020, Critical reviews in oncology/hematology.

[7]  D. Goldenberg,et al.  Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy , 2020, Expert opinion on biological therapy.

[8]  A. Bardia,et al.  Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.

[9]  Wei Li,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Sung-Bae Kim,et al.  Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01) , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[11]  H. Rugo,et al.  Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple‐negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials , 2018, Clinical breast cancer.

[12]  D. Goldenberg,et al.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target , 2018, Oncotarget.

[13]  J. McCarthy,et al.  Advances in the systemic treatment of triple-negative breast cancer. , 2018, Current oncology.

[14]  M. Djamgoz,et al.  Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. , 2018, Cancer treatment reviews.

[15]  A. Bardia,et al.  Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics , 2017, Cancer.

[16]  H. Kaplan,et al.  Triple‐negative breast cancer in the elderly: Prognosis and treatment , 2017, The breast journal.

[17]  M. Takano,et al.  UGT1A1 polymorphisms in cancer: impact on irinotecan treatment , 2017, Pharmacogenomics and personalized medicine.

[18]  L. Esserman,et al.  Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer , 2017, JAMA.

[19]  S. Hilsenbeck,et al.  Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial , 2017, JAMA.

[20]  J. Berlin,et al.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Sharma,et al.  Biology and Management of Patients With Triple-Negative Breast Cancer. , 2016, The oncologist.

[22]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Edmund A. Rossi,et al.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.

[24]  L. Dean.  Irinotecan Therapy and UGT1A1 Genotype , 2015 .

[25]  M. Shah,et al.  First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors , 2015, Clinical Cancer Research.

[26]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[27]  E. Perez,et al.  Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Olivo,et al.  Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies , 2014, Breast Cancer Research and Treatment.

[29]  C. Perou,et al.  Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. , 2014, The oncologist.

[30]  M. Pedriali,et al.  Trop-2 Is a Determinant of Breast Cancer Survival , 2014, PloS one.

[31]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[32]  Xiang Liu,et al.  Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians , 2013, The Pharmacogenomics Journal.

[33]  A. Hurria,et al.  Determining chemotherapy tolerance in older patients with cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  R. Tripaldi,et al.  Upregulation of Trop-2 quantitatively stimulates human cancer growth , 2013, Oncogene.

[35]  A. Kurian,et al.  Occurrence of breast cancer subtypes in adolescent and young adult women , 2012, Breast Cancer Research.

[36]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[37]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[38]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[39]  Henk-Jan Guchelaar,et al.  Clinical and pharmacogenetic factors associated with irinotecan toxicity. , 2008, Cancer treatment reviews.

[40]  C. Punt,et al.  UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study , 2008, British Journal of Cancer.

[41]  D. Berry,et al.  Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Giuseppe Toffoli,et al.  The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Repetto,et al.  Greater risks of chemotherapy toxicity in elderly patients with cancer. , 2003, The journal of supportive oncology.

[44]  R Yancik,et al.  Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. , 2001, JAMA.